phrykt

Wave Life Sciences, Inc. (WVE): who owns it and who trades it

As of Nov 16, 2026, WVE insiders reported 45 open-market sales worth $15.8M and 5 purchases worth $82.6M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Chris Francis (See Remarks), with $7.1M. 7 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Wave Life Sciences

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns WVE

237 funds and institutions reported WVE shares worth $1.1B at the end of Q2 2026, about 95% of the company. The largest holder is Ra Capital Management, L.P. with 14.0%.

Funds and institutions (13F) 95%Everyone else 5%

10 largest owners, by share of the company

Ra Capital Management, L.P.14.0%
BlackRock, Inc.10.0%
GSK plc9.5%
Maverick Capital Ltd5.3%
Driehaus Capital Management LLC2.8%
Primecap Management Co2.8%
683 Capital Management, LLC2.6%
FMR LLC (Fidelity)2.6%
State Street Corp2.5%
Readystate Asset Management LP2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Ra Capital Management, L.P.26.98M14.02%$157MNo change
BlackRock, Inc.19.20M9.98%$112M+36%
GSK plc18.25M9.49%$106MNo change
Maverick Capital Ltd10.28M5.34%$59.7M+1%
Driehaus Capital Management LLC5.44M2.83%$31.6M+0%
Primecap Management Co5.35M2.78%$31.1M+11%
683 Capital Management, LLC4.95M2.57%$28.8M+1%
FMR LLC (Fidelity)4.92M2.56%$28.6M-5%
State Street Corp4.84M2.52%$28.1M+32%
Readystate Asset Management LP4.73M2.46%$27.5M–
M28 Capital Management LP4.59M2.39%$26.7MNo change
Geode Capital Management, LLC3.87M2.01%$22.5M+8%
Two Sigma Investments, LP3.71M1.93%$21.5M+97%
Algert Global LLC2.82M1.46%$16.4M+114%
Qube Research & Technologies Ltd2.78M1.44%$16.1M+1680%
Squarepoint Ops LLC2.54M1.32%$14.8M+74%
Morgan Stanley2.42M1.26%$14.1M+78%
Vanguard Portfolio Management LLC2.11M1.10%$12.3M+79%
Pfizer Inc1.88M0.97%$10.9MNo change
Millennium Management LLC1.81M0.94%$10.5M+86%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, WVE insiders reported $82.6M of open-market purchases and $15.8M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$82.6M
5 trades, 2 people
Sales, 12 months
$15.8M
45 trades, 11 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 12, 2026
Filed Aug 13, 2026

Purchases and sales by month

$54.6M$54.6MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 12, 2026Adrian RawcliffeDirectorSale12,700$5.29$67.2KForm 4
Aug 11, 2026Heidi L WagnerDirectorSale7,000$6.01$42.1KForm 4
Aug 11, 2026Ken TakanashiDirectorSale3,864$6.01$23.2KForm 4
Aug 11, 2026Aik Na TanDirectorSale432$6.01$2.6KForm 4
Mar 30, 2026Ra Capital Management, L.P. +3DirectorPurchase971,091$6.50$6.3MForm 4
Mar 27, 2026Ra Capital Management, L.P. +3DirectorPurchase2.50M$6.43$16MForm 4
Mar 26, 2026Ra Capital Management, L.P. +3DirectorPurchase351,224$6.38$2.2MForm 4
Mar 26, 2026Ra Capital Management, L.P. +3DirectorPurchase4.95M$6.06$30MForm 4
Feb 26, 2026Chris FrancisSee RemarksSale17,900$15.09$270KForm 4
Feb 26, 2026Chris FrancisSee RemarksSale15,294$15.00$229KForm 4
Feb 9, 2026Kyle MoranCFOSale3,588$13.45$48.3KForm 4
Feb 9, 2026Paul BolnoCEOSale10,480$13.45$141KForm 4
Feb 9, 2026Chris FrancisSee RemarksSale1,883$13.45$25.3KForm 4
Feb 9, 2026Chandra VargeeseSee RemarksSale3,228$13.45$43.4KForm 4
Jan 2, 2026Chris FrancisSee RemarksSale1,295$16.70$21.6KForm 4
Jan 2, 2026Chris FrancisSee RemarksSale8,080$15.92$129KForm 4
Dec 11, 2025GSK plc10% ownerPurchase1.47M$19.00$27.9MForm 4
Dec 9, 2025Kyle MoranCFOSale50,000$20.03$1MForm 4
Dec 9, 2025Kyle MoranCFOSale36$20.25$729Form 4
Dec 8, 2025Adrian RawcliffeDirectorSale42,000$15.00$630KForm 4
Dec 8, 2025Heidi L WagnerDirectorSale7,000$14.00$98KForm 4
Dec 8, 2025Heidi L WagnerDirectorSale7,000$13.00$91KForm 4
Dec 8, 2025Christian O HenryDirectorSale42,000$12.75$536KForm 4
Dec 8, 2025Christian O HenryDirectorSale30,000$18.02$541KForm 4
Dec 8, 2025Christian O HenryDirectorSale15,000$14.07$211KForm 4
Dec 8, 2025Christian O HenryDirectorSale6,445$12.75$82.2KForm 4
Dec 8, 2025Aik Na TanDirectorSale21,000$12.75$268KForm 4
Dec 8, 2025Aik Na TanDirectorSale25,000$15.00$375KForm 4
Dec 8, 2025Aik Na TanDirectorSale20,000$12.75$255KForm 4
Dec 8, 2025Aik Na TanDirectorSale17,230$15.00$258KForm 4
Dec 8, 2025Aik Na TanDirectorSale15,000$12.75$191KForm 4
Dec 8, 2025Aik Na TanDirectorSale7,494$12.75$95.5KForm 4
Dec 8, 2025Aik Na TanDirectorSale7,494$15.00$112KForm 4
Dec 8, 2025Gregory L. VerdineDirectorSale12,020$13.09$157KForm 4
Dec 8, 2025Gregory L. VerdineDirectorSale7,980$14.05$112KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale22,500$14.08$317KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale28,125$14.50$408KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale107,400$14.56$1.6MForm 4
Dec 8, 2025Chris FrancisSee RemarksSale45,882$14.50$665KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale9,375$15.00$141KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale37,500$14.08$528KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale17,900$15.00$268KForm 4
Dec 8, 2025Chris FrancisSee RemarksSale122,349$14.20$1.7MForm 4
Dec 8, 2025Chris FrancisSee RemarksSale50,000$16.00$800KForm 4
Dec 8, 2025Kyle MoranCFOSale60,000$13.20$792KForm 4
Dec 8, 2025Kyle MoranCFOSale50,000$13.20$660KForm 4
Dec 8, 2025Kyle MoranCFOSale50,000$15.00$750KForm 4
Dec 8, 2025Kyle MoranCFOSale50,000$18.00$900KForm 4
Dec 8, 2025Mark CorriganDirectorSale9,600$13.09$126KForm 4
Dec 8, 2025Mark CorriganDirectorSale6,515$14.07$91.7KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Ra Capital Management, L.P.Director, 10% owner$54.6M–Mar 30, 2026
GSK plc10% owner$27.9M–Dec 11, 2025
Chris FrancisSee Remarks–$7.1MFeb 26, 2026
Kyle MoranChief Financial Officer–$4.2MFeb 9, 2026
Aik Na TanDirector–$1.6MAug 11, 2026
Christian O HenryDirector–$1.4MDec 8, 2025
Adrian RawcliffeDirector–$697KAug 12, 2026
Gregory L. VerdineDirector–$269KDec 8, 2025
Heidi L WagnerDirector–$231KAug 11, 2026
Mark CorriganDirector–$217KDec 8, 2025
Paul BolnoPresident and CEO, Director–$141KFeb 9, 2026
Chandra VargeeseSee Remarks–$43.4KFeb 9, 2026
Ken TakanashiDirector–$23.2KAug 11, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

WVE short interest

High short interest. 10.5% of WVE shares are sold short: about 1 share in 10. Over the last 12 reports the number of shares short went up 16%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 20.65M WVE shares were sold short, 10.5% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 3.06M shares, buying them all back would take about 6.8 trading days (days to cover).

Shares short, % of all shares

10.5%May 15Oct 3011.3%

Days to cover

6.8May 15Oct 307.9

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202620.65M10.47%-2%3.06M6.8
Oct 15, 202621.17M10.74%+14%3.24M6.5
Sep 30, 202618.56M9.42%+5%3.26M5.7
Sep 15, 202617.64M8.95%+8%3.41M5.2
Aug 31, 202616.28M8.26%+0%2.96M5.5
Aug 14, 202616.20M8.22%-1%3.69M4.4
Jul 31, 202616.40M8.32%-3%2.20M7.5
Jul 15, 202616.85M8.76%-19%2.67M6.3
Jun 30, 202620.90M10.87%+15%3.68M5.7
Jun 15, 202618.15M9.44%-2%3.25M5.6
May 29, 202618.53M9.63%+4%4.05M4.6
May 15, 202617.77M9.24%+6%4.28M4.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Wave Life Sciences company events

Wave Life Sciences filed 14 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Oct 27, 2026.

  1. Oct 27, 2026ResultsReleased financial results. Filing
  2. Jul 30, 2026ResultsReleased financial results. Filing
  3. Jun 26, 2026VoteReported shareholder vote results. Filing
  4. May 18, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the title of the press release, the fourth paragraph, tenth paragraph, and eleventh paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial… Filing
  5. Apr 28, 2026ResultsReleased financial results. Filing
  6. Apr 21, 2026AnnouncementWave Life Sciences Ltd. issued a press release entitled “Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States.” The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Filing
  7. Apr 15, 2026AgreementWave Life Sciences Ltd., a public company limited by shares incorporated under the laws of the Republic of Singapore, announced that it has decided to restructure its corporate group to cause the parent company of the group to be a Delaware corporation. Filing
  8. Mar 26, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the second and the tenth paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
  9. Feb 26, 2026ResultsReleased financial results. Filing
  10. Feb 2, 2026AnnouncementWave Life Sciences Ltd. issued a press release entitled “Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency.” The press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein. Filing
  11. Jan 12, 2026ResultsReleased financial results. Filing
  12. Dec 11, 2025AgreementWave Life Sciences Ltd. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc., as representatives of the several underwriters named therein, relating to the issuance and sale in an underwritten public offering by the Company of an aggregate of… Filing
  13. Dec 8, 2025AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the title of the press release, the third paragraph, sixth paragraph, including the graphic therein, and ninth paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form… Filing
  14. Nov 17, 2025AnnouncementShared information with investors. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Wave Life Sciences financials

Famous investors that hold WVE

7 of the 50 well-known investors we track reported holding WVE in their latest 13F filing. The largest position is Lee Ainslie's, worth $36M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Lee Ainslie · Maverick CapitalQ3 20269.72M$36M0.3%New
Jim Simons · Renaissance TechnologiesQ3 20262.19M$8.1M0.0%New
Ken Griffin · Citadel AdvisorsQ3 20261.53M$5.7M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 20261.14M$4.2M0.0%New
Israel Englander · Millennium ManagementQ3 2026809,532$3M0.0%New
Stanley Druckenmiller · Duquesne Family OfficeQ3 2026173,000$640K0.0%New
Paul Tudor Jones · Tudor Investment CorpQ3 202693,355$345K0.0%New

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named WVE in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Maverick Capital, Ltd.13G/A0.0%
Nov 16, 2026Maverick Capital, Ltd.13G/A0.0%
Oct 27, 2026BlackRock, Inc.13G6.8%
Oct 27, 2026BlackRock, Inc.13G6.8%
Oct 27, 2026BlackRock, Inc.13G/A0.0%
Oct 27, 2026BlackRock, Inc.13G/A0.0%

Questions about Wave Life Sciences, Inc. (WVE) stock

Who owns the most WVE stock?

The largest reported owner of Wave Life Sciences, Inc. (WVE) is Ra Capital Management, L.P., with 14.0% of the company. In total, 237 funds and institutions reported holding WVE at the end of Q2 2026, together about 95% of the shares. See the largest owners.

Are WVE insiders buying or selling?

In the last 12 months, WVE insiders reported 5 open-market purchases worth $82.6M and 45 sales worth $15.8M. The latest trade was on Aug 12, 2026. See every trade.

What is the short interest in WVE?

As of Oct 30, 2026, 20.65M WVE shares were sold short, 10.5% of the shares outstanding, down 2.4% from the report before. At the average daily volume of 3.06M shares, buying them all back would take about 6.8 trading days (days to cover). See the history.

Which famous investors hold WVE?

7 of the 50 well-known investors we track reported WVE in their latest 13F filing, including Lee Ainslie, Jim Simons, Ken Griffin. The largest position is worth $36M. See all holders.

Executive pay

Wave Life Sciences's chief executive was paid a total of $12.3M for the year ended Dec 31, 2025, up 187% from $4.3M the year before. In the last 12 months, Wave Life Sciences's executives and directors bought no stock on the open market and sold $15.8M.

Chief executive, total pay$12.3MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$18.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.